Get the Weekly Intelligence Brief — top committee picks every Sunday.
HUM · NASDAQ · STOCK

Humana

Healthcare Updated August 09, 2026
$385.07
52W $163.11 – $428.88
53/100
$46.23B
36.2
0.74
AI Committee Verdict
Watch
53/100
Conviction: Contested · 50% agreement · 6 analysts
-37.7%
Contested

Is HUM Bullish or Bearish?

Mixed. Innellis AI committee rates Humana (HUM) Watch with a composite score of 53/100 , based on 6 analysts with 50% agreement. Last updated August 09, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +7.16 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -12.84 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case — market regime is bullish (bull market -- normal position sizing). Risk Analyst remains cautious — current ratio of 0.01 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • 5 consecutive earnings beats -- consistent execution — Growth
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
  • News sentiment is positive (+0.27 across 90 articles, 14d) — News
Bear Case
  • P/E of 36.1 is moderate-to-rich — Value
  • EPS declining -19.0% YoY despite any revenue growth — Growth
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • MACD histogram negative -- bearish momentum — Technical
  • Current ratio of 0.01 is tight -- limited short-term liquidity cushion — Risk
  • Bollinger bandwidth of 16.9% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 09, 2026
Overall Committee Score
53/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 88%
of 95 Healthcare peers
Value Analyst neutral
48 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− P/E of 36.1 is moderate-to-rich
Growth Analyst neutral
50 / 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− EPS declining -19.0% YoY despite any revenue growth
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst bearish
35 / 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.01 is tight -- limited short-term liquidity cushion
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
66 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 90 articles, 14d)
Portfolio Manager neutral
55 / 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 4 existing position pair(s) are highly correlated already
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 55.4 to 52.8.

Analyst-level changes:
  • Growth Analyst: score 58->50 (-8); +1 bearish signal(s).
  • Risk Analyst: +1 bearish signal(s).
  • Value Analyst joined: neutral at 48.

Comparing 2026-08-08 to 2026-08-09 (1 day apart).

Technical Analysis

RSI (14)
57.6
Neutral
MACD Histogram
-2.999
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.49
Inside Bands
Price vs Moving Averages
EMA 9
$374.24 Above
EMA 21
$378.53 Above
EMA 50
$361.55 Above
EMA 200
$289.87 Above

Fundamental Analysis

Valuation
67
Growth
69
Profitability
16
Financial Health
83
Cash Flow
15
Valuation
P/E Ratio 36.2×
P/B Ratio 2.41×
PEG Ratio -1.95
Dividend Yield 0.92%
52W High $428.88
52W Low $163.11
Quality & Growth
ROE 672.8%
ROA 243.7%
Gross Margin 1365.3%
Operating Margin 138.8%
Revenue Growth YoY
Debt / Equity 0.74
AI Fundamental Assessment
P/E ratio of 36.2 (rich relative to a 15-40x range); Price-to-book of 2.4x; PEG ratio of -2.0 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 6.7%; Return on assets of 2.4%; Net margin of 0.9%; Gross margin of 13.7%; Current ratio of 1.74 (healthy short-term liquidity); Debt-to-equity of 0.74; Free cash flow per share is negative (-3.69); Most recent quarter beat estimates by 4.3%; 5 consecutive earnings beats; EPS growth decelerating (+360.4% -> -26.2% QoQ); Average YoY EPS growth of 21.4%; Analyst estimates rising over recent quarters
Get the Full HUM Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore HUM Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime